Kirsty

Insulin Aspart, the active ingredient in Kirsty, is a rapid‑acting insulin analog presented as a sterile solution for subcutaneous and intravenous use. It is used to control blood glucose levels in people with diabetes mellitus, including both type 1 and type 2 disease.

GNH USA supplies Kirsty as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kirsty (Insulin Aspart) is employed in the management of diabetes mellitus, targeting rapid post‑prandial glucose control.

- Type 1 diabetes mellitus: provides fast‑acting insulin to replace deficient endogenous insulin. - Type 2 diabetes mellitus: used as a mealtime bolus to improve glycemic control alongside basal therapy. - Post‑prandial hyperglycemia: delivers rapid glucose reduction after meals to prevent spikes.

The most frequently reported adverse reactions with rapid‑acting insulin analogues such as Kirsty are related to glucose regulation and injection site tolerance.

Common Side Effects: - Hypoglycemia: low blood glucose levels, often presenting with sweating, tremor, or confusion. - Injection site pain: mild discomfort or erythema at the injection site. - Lipodystrophy: localized thickening or loss of subcutaneous fat with repeated injections. - Weight gain: modest increase in body weight associated with improved glycemic control.

Serious or Rare Side Effects: - Severe hypoglycemia: profound low glucose requiring assistance or medical intervention. - Allergic reaction: urticaria, angioedema, or anaphylaxis following administration. - Hypersensitivity at the injection site: persistent swelling, redness, or induration. - Vision changes: transient visual disturbances linked to rapid glucose shifts.

When using Kirsty, clinicians should observe several precautionary measures to ensure safe and effective therapy.

- Monitor blood glucose: check glucose levels before and after dosing to avoid hypoglycemia. - Adjust dose during exercise: reduce insulin amount if increased physical activity is planned. - Avoid use in existing hypoglycemia: do not administer if blood glucose is already low. - Use with caution in renal impairment: impaired clearance may increase insulin effect. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kirsty may interact with other medicines, altering its glucose‑lowering effect or masking symptoms.

Major Interactions (Avoid): - Sulfonylureas: combined use can cause additive hypoglycemia. - Beta‑blockers: may conceal typical hypoglycemia warning signs.

Moderate Interactions (Monitor Closely): - ACE inhibitors: may enhance insulin sensitivity, requiring dose adjustment. - Thiazide diuretics: can raise blood glucose, potentially reducing insulin efficacy. - Oral contraceptives: hormonal changes may affect glucose control and insulin requirements.